Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | PDGFRB N666K |
| Gene Variant Detail | |
| Relevant Treatment Approaches | PDGFR Inhibitor (Pan) PDGFR-beta Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| PDGFRB N666K | Advanced Solid Tumor | sensitive | PDGFR Inhibitor (Pan) | Imatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gleevec (imatinib) inhibited PDGFRB downstream signaling and proliferation of transformed cells expressing PDGFRB N666K in culture (PMID: 26455322). | 26455322 |
| PDGFRB N666K | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited PDGFRB downstream signaling and proliferation of transformed cells expressing PDGFRB N666K in culture (PMID: 26455322). | 26455322 | |
| PDGFRB N666K | Advanced Solid Tumor | sensitive | PDGFR Inhibitor (Pan) | Nilotinib | Preclinical - Cell culture | Actionable | In a preclinical study,Tasigna (nilotinib) inhibited PDGFRB downstream signaling and proliferation of transformed cells expressing PDGFRB N666K in culture (PMID: 26455322). | 26455322 |
| PDGFRB N666K | Advanced Solid Tumor | sensitive | PDGFR Inhibitor (Pan) | Imatinib | Preclinical - Biochemical | Actionable | In a preclinical study, Gleevec (imatinib) treatment inhibited Pdgfrb activity in a reporter assay in a cell line expressing PDGFRB N666K (PMID: 39580648). | 39580648 |